Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 4/2017

01-04-2017 | Case Based Review

Recovery of nail dystrophy potential new therapeutic indication of tofacitinib

Authors: Jose A. Jaller, Juan J. Jaller, Antonio M. Jaller, Juan J. Jaller-Char, Sineida Berbert Ferreira, Rachel Ferreira, Morton Scheinberg

Published in: Clinical Rheumatology | Issue 4/2017

Login to get access

Abstract

Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy.
Literature
1.
Lam S (2016) JAK inhibitors:a broadening approach in rheumatoid arthritis. Drugs Today 52:467–469CrossRefPubMed
2.
Fleischmann R1, Mease PJ2, Schwartzman S3, Hwang LJ4, Soma K5, Connell CA5, Takiya L6, Bananis E7 (2017) Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol 36(1):15–24CrossRefPubMed
3.
Roskoski R (2016) Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784–803CrossRefPubMed
4.
Kostovic K, Gulin SJ, Mokos ZB, Ceovic R (2017) Tofacitinib an oral Janus kinase inhibitor: perspectives in dermatology Curr Med Chem Jan 2012
5.
Kasumagic-Halilovic E, Prohic A (2009) Nail changes in alopecia areata: frequency and clinical presentation. J Eur Acad Dermatol Venereol 23:240–241CrossRefPubMed
6.
Craiglow BG, King BA (2014) Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 134:2988–2990CrossRefPubMed
7.
Scheinberg M, Ferreira SB (2016) Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med 165:750–751CrossRefPubMed
8.
Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB (2016) Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol 8(3):262–266CrossRefPubMedPubMedCentral
9.
Tosti A, Fanti PA, Morelli R, Bardazzi F (1991) Trachyonychia associated with alopecia areata: a clinical and pathological study. J Am Acad Dermatol 25:266–270CrossRefPubMed
10.
Dhayalan A, King BA (2016) Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol 152:492–493CrossRefPubMed
11.
Gao Q, Liang X, Shaikh AS, Zang J, Xu W, Zhang Y (2016) JAK/STAT signal transduction: promising attractive targets for immune, inflammatory and hematopoietic diseases. Curr Drug Targets 7
12.
Liu LY, Craiglow BG, Dai F, King BA (2016) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol pii: S0190–9622(16)30763–0
Metadata
Title
Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
Authors
Jose A. Jaller
Juan J. Jaller
Antonio M. Jaller
Juan J. Jaller-Char
Sineida Berbert Ferreira
Rachel Ferreira
Morton Scheinberg
Publication date
01-04-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3574-0

Other articles of this Issue 4/2017

Clinical Rheumatology 4/2017 Go to the issue

Original Article

Neutrophil extracellular traps in neuropathy with anti-neutrophil cytoplasmic autoantibody-associated microscopic polyangiitis

Original Article

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry

Original Article

Are obesity, ACPAs and periodontitis conditions that influence the risk of developing rheumatoid arthritis in first-degree relatives?

Original Article

Pachymeningitis in granulomatosis with polyangiitis: case series with earlier onset in younger patients and literature review

Original Article

Putting recommendations into practice: Australian rheumatologists’ opinions on leflunomide use in rheumatoid arthritis

Review Article

Did King Herod suffer from a rheumatic disease?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits